Investor Relations

Investors

We are a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions.

Our lead investigational product is laromestrocel (Lomecel-B™), which is derived from culture-expanded mesenchymal stem cells (MSCs) that are sourced from bone marrow of young healthy adult donors. We believe that by using the same cells that promote tissue repair, organ maintenance, and immune system function, we can develop safe and effective therapies for some of the most difficult diseases and conditions associated with aging.

Latest News

Corporate Presentation

Latest Quarterly Reports

View All Financial Reports
Opens in a new window